Amundi Has $148.96 Million Stock Position in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Amundi grew its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 45.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,726,902 shares of the company’s stock after buying an additional 542,944 shares during the period. Amundi owned 0.38% of GE HealthCare Technologies worth $148,963,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. Larson Financial Group LLC grew its stake in shares of GE HealthCare Technologies by 21.2% during the fourth quarter. Larson Financial Group LLC now owns 3,807 shares of the company’s stock worth $298,000 after purchasing an additional 665 shares during the period. Machina Capital S.A.S. acquired a new stake in shares of GE HealthCare Technologies during the fourth quarter worth $765,000. Andra AP fonden grew its stake in shares of GE HealthCare Technologies by 431.6% during the fourth quarter. Andra AP fonden now owns 50,500 shares of the company’s stock worth $3,948,000 after purchasing an additional 41,000 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors grew its stake in shares of GE HealthCare Technologies by 2.1% during the fourth quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 7,297 shares of the company’s stock worth $571,000 after purchasing an additional 153 shares during the period. Finally, Callan Family Office LLC acquired a new stake in shares of GE HealthCare Technologies during the fourth quarter worth $1,344,000. 82.06% of the stock is owned by institutional investors and hedge funds.

GE HealthCare Technologies Stock Performance

Shares of GE HealthCare Technologies stock opened at $85.36 on Tuesday. The firm has a market cap of $39.03 billion, a price-to-earnings ratio of 19.71, a price-to-earnings-growth ratio of 3.19 and a beta of 1.13. The stock’s 50-day moving average is $86.91 and its 200-day moving average is $86.17. GE HealthCare Technologies Inc. has a one year low of $74.51 and a one year high of $94.80. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 0.83.

GE HealthCare Technologies (NASDAQ:GEHC) last released its earnings results on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.19. The business had revenue of $5.32 billion for the quarter, compared to the consensus estimate of $5.33 billion. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. Equities analysts predict that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GEHC has been the topic of several recent analyst reports. Wells Fargo & Company lifted their target price on GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Jefferies Financial Group upgraded GE HealthCare Technologies from a “hold” rating to a “buy” rating and lifted their target price for the stock from $95.00 to $103.00 in a report on Wednesday, January 8th. Finally, Citigroup lifted their target price on GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $97.67.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.